Korro to Participate in Upcoming September Investor and Scientific Conferences
Here's Why We're Watching Korro Bio's (NASDAQ:KRRO) Cash Burn Situation
BMO Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Korro Bio(KRRO.US), With a Forecast Between $100 to $180
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO) and Gilead Sciences (GILD)
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
Korro Bio GAAP EPS of -$2.43 Beats by $0.29
Korro Bio Is Maintained at Outperform by RBC Capital
Korro Bio Shares Are Trading Higher Following Q2 Financial Results. Also, William Blair Initiated Coverage on the Stock With an Outperform Rating.
Express News | Korro Bio Shares Are Trading Higher Following Q2 Financial Results. Also, William Blair Initiated Coverage on the Stock With an Outperform Rating
Korro Bio Analyst Ratings
RBC Adjusts Korro Bio's PT to $95 From $105, Keeps Outperform Rating, Speculative Risk
RBC Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Cuts Target Price to $95
Express News | Korro Bio Inc : William Blair Initiates Coverage With Outperform Rating
Analysts Offer Insights on Healthcare Companies: IO Biotech (IOBT), Gritstone Oncology (GRTS) and Korro Bio (KRRO)
Buy Rating on Korro Bio Amid Strong KRRO-110 Preclinical Results and Upcoming Clinical Milestones
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $100
Express News | Korro Bio Inc : RBC Cuts Target Price to $95 From $105
Express News | Korro Bio Inc - Qtrly Shr Loss $ 2.43
Express News | Korro Bio Inc - Cash Runway Into Second Half of 2026 to Fund Anticipated Completion of Krro-110 Fih Trial and Progress Additional Pipeline Candidates
No Data